为什么和如何酸盐可能使恶性瘤对免疫疗法的敏感
Philippe Icard1, Mathilde Prieto2, Antoine Coquerel3
1INSERM U1086 ANTICIPE, Interdisciplinary Research Unit for Cancers Prevention and Treatment, BioTICLA Laboratory, Université de Caen Normandie, Caen, France; Thoracic Surgery Department, Cochin Hospital, Paris Center University Hospitals, AP-HP, Paris, France.
将免疫检查点抑制剂与酸结合起来,可能会增强癌症免疫疗法. 这一策略针对癌细胞代谢,可能增强抗瘤免疫力,改善固体瘤治疗的疗效.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢途径 代谢途径
背景情况:
- 固体瘤中的免疫疗法疗效受到抵抗机制的限制.
- 癌细胞利用有氧糖解,耗尽葡萄糖,并在瘤微环境 (TME) 中增加乳酸.
- 这种新陈代谢重编程会耗尽细胞毒性免疫细胞,并支持免疫抑制细胞.
研究的目的:
- 研究将免疫检查点抑制剂 (ICI) 与酸 (SCT) 结合用于固体瘤治疗的潜力.
- 评估SCT对癌细胞代谢和抗瘤免疫反应的影响.
主要方法:
- 进行了临床前研究,以评估SCT的影响.
- 研究了SCT对癌细胞生长,死亡和化疗有效性的影响.
- 分析了TME的变化,包括葡萄糖可用性,乳酸水平和免疫细胞功能.
主要成果:
- 酸抑制了癌细胞的新陈代谢,减少了生长,促进了细胞死亡.
- SCT增强了化疗的有效性.
- 在TME中,SCT增加了葡萄糖的可用性和减少了乳酸.
- 临床前数据显示,T细胞透,激活和巨细胞再极化向抗瘤表型的增强.
结论:
- 将ICI与SCT结合起来是一种有前途的策略,可以克服固体瘤的耐药性.
- 通过调节TME和免疫细胞功能,SCT可能会增强抗瘤免疫力.
- 这种简单而具有成本效益的方法可以证明临床试验有助于改善免疫治疗结果.
更多相关视频
09:01Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
相关概念视频
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Tumor Microenvironment
